---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-114983"
form_type: "8-K"
ticker: "LQDA"
cik: "0001819576"
company_name: "Liquidia Corp"
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T17:00:03.024058+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Liquidia Q3 net loss $15.8M; YUTREPIA PH-ILD PDUFA Jan 24, 2024

## Summary
- Net loss $15.8M ($0.24/sh) vs $9.1M ($0.14/sh) in Q3 2022; cash $76.2M vs $93.3M at year-end.
- Revenue $3.7M (+15% YoY) from Sandoz treprostinil injection promotion agreement.
- R&D spend up 65% to $7.4M on YUTREPIA pre-launch; G&A up 57% to $10.6M on litigation and commercial prep.
- PDUFA date for PH-ILD label expansion Jan 24, 2024; final approval delayed to Mar 31, 2024 due to Tyvaso exclusivity.
- Oral arguments in '793 patent appeal set for Dec 4, 2023; CAFC ruling could enable final YUTREPIA approval.

## SEC filing metadata
- accession: 0001104659-23-114983
- form_type: 8-K
- ticker: LQDA
- cik: 0001819576
- company_name: Liquidia Corp
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819576/000110465923114983/0001104659-23-114983-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819576/000110465923114983/tm2329950d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-114983
- JSON: https://secwatch.observer/filing/0001104659-23-114983.json
- Plain text: https://secwatch.observer/filing/0001104659-23-114983.txt

## Key facts
- Earnings Releases
  Liquidia Corp reported the third quarter ended September 30, 2023 results: revenue $3.7 million.
  - Period: the third quarter ended September 30, 2023
  - Revenue: $3.7 million
  - Result: reported results
  source text: for PAH and PH-ILD. Third Quarter 2023 Financial Results Cash totaled $76.2 million as of September 30, 2023, compared to $93.3 million as of December 31, 2022. Revenue was $3.7 million for the three months ended September 30, 2023, compared to $3.2 million for the three months ended September 30, 2022. Revenue related primarily to the promotion agreement
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819576/000110465923114983/0001104659-23-114983-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.